The Changing Landscape of Global Vaccine Development and Market Potential - - BioPharm International

ADVERTISEMENT

The Changing Landscape of Global Vaccine Development and Market Potential


BioPharm International
Volume 20, Issue 10

ABSTRACT



Vaccines stimulate the body's immune system to prevent or control specific diseases. Vaccines against major human infectious diseases such as pertussis, diphtheria, tetanus, and tuberculosis were developed in the early 1900s, and those for polio, mumps, measles, and rubella were not licensed until the 1960s. Because of the widespread use and effectiveness of antibiotics, and the low profit margins and liabilities associated with vaccine products, interest in vaccines diminished in the 1980s and early 1990s. The recent renaissance in vaccines is fueled by multiple factors. New developments in modern biotechnology and immunology have made it possible to produce novel antigens and create new vaccine technologies. The recent licensures of high-profile vaccine products not only offered major contributions to human health but also achieved significant commercial success for the developers. These include Prevnar, a pneumococcal glycoconjugate vaccine; Gardasil, a human papilloma virus (HPV) vaccine; Rotarix and Rotateq, rotavirus vaccines; and Zostavax, the herpes zoster vaccine. Other factors include concerns over possible pandemic flu outbreaks and bioterrorism, the emergence of antibiotic-resistant pathogens, and increased funding from both private and public sectors. The current vaccine market is estimated at about $10 billion worldwide and is expected to double in the next five years.


Table 1. Vaccines licensed in the US
Vaccines currently licensed in the US are listed in Table 1.1 Vaccines can be divided into four broad categories: live attenuated vaccines, inactivated vaccines, subunit vaccines, and conjugated vaccines. Live vaccines are usually weakened viruses or bacteria that are no longer capable of causing diseases but can still stimulate immune response in the hosts. Good examples are MMR II, Flumist, and Rotateq. Inactivated vaccines are composed of killed virus or bacteria, such as the polio virus vaccine and the rabies vaccine. Subunit vaccines are made from one or more components of a microorganism. Examples are the Streptococcus pneumoniae polysaccharides vaccines and the recombinant Hepatitis B vaccines. Conjugated vaccines are prepared by conjugating a subunit to a carrier protein or other immuno-stimulating agents. An example is Prevnar (7-valent capsular polysaccharides of S. pneumoniae conjugated to a carrier protein CRM197).

NEW VACCINE TECHNOLOGIES


Table 2. New vaccine technologies
Significant efforts have been undertaken to identify and develop new vaccine technologies (Table 2).2–3 Inactivated pathogens, recombinant proteins or peptides (with or without adjuvants) are inefficient in inducing T-cell response. Plasmid DNA-based vaccines elicit strong antibody and T-cell responses in animals. Attempts to enhance immune responses to DNA vaccines in humans have been made using new formulations with cationic lipids, electroporation, or the incorporation of cytokine genes in the construction, with promising results. Viral–vector based vaccines tested in humans include attenuated pox viruses (vaccinia or avipox viruses) or adenovirus. Lipopeptides, presenting peptide antigens in association with a lipid moiety, have also been synthesized and tested as candidate vaccines against HBV, HPV, and HIV-1 infections to induce T-cell responses. Transgenic plants, expressing antigens from various pathogens, have been evaluated for vaccination through the oral route, and generated encouraging results when tested in animals. Monocyte-derived dendritic cells, loaded with antigens (presented as peptides, proteins, RNA or recombinant viruses), have generated good results in cancer patients.

No single vector alone can elicit optimal immune responses in humans. Thus, there is a trend to use multiple vectors as part of mixed immunization regimens. In such heterologous prime–boost vaccination schemes, the antigen is presented to the immune system using a "priming" vector. A second vector is used as a booster to present the very same antigen. Collectively, such mixed immunization regimens have been shown to elicit stronger antibody, T-cell, and cytotoxic T lymphocyte responses. Association between DNA and pox viruses or vaccinia and canarypox appears to be particularly promising in inducing effective immune responses.


blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

FDA Approves Pfizer's Trumenba for the Prevention of Meningitis B
October 30, 2014
EMA: Extrapolation Across Indications for Biosimilars a Possibility
October 30, 2014
Bristol-Myers Squibb Announces Agreement to Acquire HER2-Targeted Cancer Treatment
October 29, 2014
Contract Research and Manufacturing Organization Paragon Bioservices Raises $13 Million
October 28, 2014
Yale and Gilead Extend Sequencing Initiative
October 28, 2014
Author Guidelines
Source: BioPharm International,
Click here